Aktuellt
SENASTE
Redeye resumes its coverage and updates its view on BeammWave after BeammWave concluded its right issue. After the rights issue and conditional on a successful warrant exercise rate, Redeye believes BeammWave has sufficient funding. The Highlight of Q1 2024 was that BeammWave booked its first net sales as the Molex project was delivered. Redeye adjusts its estimates and fair value range.
LÄS MER
